Combining Molecular and Traditional Prognostic Factors: A Holistic Approach to Breast Cancer Prognostication
Open Access
- 7 July 2024
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 14 (13) , 1449
Abstract
Breast cancer is a heterogeneous disease with various morphologies and molecular features, and it is the second leading cause of cancer death in women in developed countries. According to the literature, we currently lack both prognostic biomarkers and therapeutic targets. The most important prognostic factors are disease stage and Nottingham grade. We conducted a retrospective analysis involving 273 patients with BC who underwent neoadjuvant therapy before proceeding to curative surgical treatment between 1 January 2014 and 31 December 2023. Pathological procedures were conducted at the Department of Pathology, Emergency County Hospital of Targu Mureș, Romania. A statistical analysis was performed. Regarding the relationship between Nottingham grade and Ki67, grade I was associated with a Ki67 of less than 14. The relationship between tumor grade and luminal was similar (p = 0.0001): Grade I was associated with luminal A. Regarding TNM stage, it was statistically significantly correlated with TILs (p = 0.01) and RCB (p = 0.0001). Stages III and IV were associated with a high RCB and poor prognosis. Regarding the prognostic value, Nottingham grade 3 and TNM stages III and IV were correlated with low overall survival and disease-free survival, with poor prognosis, and, among the molecular variables, RCB played the most important prognostic role.Keywords
This publication has 40 references indexed in Scilit:
- Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trialJournal for ImmunoTherapy of Cancer, 2023
- Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer SubtypesThe Oncologist, 2022
- Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patientsThe Lancet Oncology, 2021
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Groupnpj Breast Cancer, 2021
- Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-BioscoreBritish Journal of Cancer, 2021
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancernpj Breast Cancer, 2020
- Exploring specific prognostic biomarkers in triple-negative breast cancerCell Death & Disease, 2019
- ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti‐HER2 therapy using transcriptomic data of 3,104 breast cancer patientsInternational Journal of Cancer, 2019
- Prognostic and Predictive Biomarkers: Tools in Personalized OncologyMolecular Diagnosis & Therapy, 2014
- An overview of prognostic factors for long-term survivors of breast cancerBreast Cancer Research and Treatment, 2007